http://www.redacre.com/hourly1.0 http://www.redacre.com/insightsdaily0.6 http://www.redacre.com/insights/rss.xmlalways0.7 http://www.redacre.com/sectorwatch/healthcarehourly0.9 http://www.redacre.com/users/rajesh-patel-phdmonthly http://www.redacre.com/insights/2012/oct/23/questcor-trading-pattern-signals-large-move-likely-near-term2014-05-27T01:47Znever http://www.redacre.com/insights/2012/sep/10/seeking-alpha-acadia-pharmaceuticals-poised-100-gain-december2014-05-27T01:49Znever http://www.redacre.com/insights/2013/dec/30/durects-atm-facility-feedback-their-cfo2014-06-08T12:44Znever http://www.redacre.com/weeklyreview/2014/jan/19/week-ending-january-17-20142014-05-09T10:35Znever http://www.redacre.com/insights/0411211161/real-life-left-twix-right-twix-story-sneakers-and-stocks2021-11-07T16:43Znever http://www.redacre.com/insights/1205251162/stock-strategy-session-may-8-20252025-05-24T12:36Zhourly http://www.redacre.com/insights/2205251163/unitedhealths-penalty-box-plotline-heres-how-movie-ends2025-05-24T12:37Zhourly http://www.redacre.com/insights/2305251164/stock-strategy-session-may-22-20252025-05-24T12:35Zhourly http://www.redacre.com/weeklyreview/2014/feb/02/week-ending-january-31-20142014-05-28T18:31Znever http://www.redacre.com/marketnotes/2014/mar/09/mannkind-extends-cash-runway2014-06-24T09:20Znever http://www.redacre.com/marketnotes/2014/mar/09/synergy-puts-atm-place2014-06-24T09:19Znever http://www.redacre.com/marketnotes/2014/mar/09/northwest-biotherapeutics-gives-interim-update-sort2014-06-24T09:16Znever http://www.redacre.com/weeklyreview/2014/mar/30/weekly-review-march-28-2014-success-failure-cash-raise-and-selloff2014-03-31T14:01Znever http://www.redacre.com/marketnotes/2014/mar/31/late-march-biotech-selloff-victim-political-gamesmanship2025-04-28T22:47Zmonthly http://www.redacre.com/marketnotes/2014/apr/06/highly-positive-advisory-committee-vote-points-approval-afrezza2014-06-24T09:27Znever http://www.redacre.com/marketnotes/2014/apr/06/pfizer-reports-palbociclib-plus-letrozole-nearly-doubles-progression-free2014-06-24T09:28Znever http://www.redacre.com/weeklyreview/2014/apr/06/political-gamesmanship-positive-ad-comm-and-highly-anticipated-data-weekly2014-06-08T12:52Znever http://www.redacre.com/marketnotes/2014/apr/11/ironwood-pharmaceuticals-starts-tv-ads-linzess2014-06-24T09:33Znever http://www.redacre.com/marketnotes/2014/apr/13/merck-reports-positive-hepatitis-c-data2014-06-24T09:33Znever http://www.redacre.com/marketnotes/2014/apr/13/questcor-be-acquired-mallinckrodt2014-06-24T09:33Znever http://www.redacre.com/weeklyreview/2014/apr/14/acquisition-and-ad-campaign-and-promising-trial-results-weekly-review-april2014-04-17T23:09Znever http://www.redacre.com/weeklyreview/2014/apr/21/q1-2014-biotech-earnings-preview2014-10-27T10:16Znever http://www.redacre.com/weeklyreview/2014/apr/27/mergers-earnings-and-trial-failures-oh-my-week-ending-april-252014-04-28T10:16Znever http://www.redacre.com/insights/2012/nov/02/questcor-cerium-pharmaceuticals-connection2012-11-21T11:40Znever http://www.redacre.com/insights/040614160/3-steps-find-good-stocks-they-make-huge-moves2015-05-22T11:19Znever http://www.redacre.com/insights/270614161/biotech-investing-red-flag-dont-fall-companys-line2014-07-01T08:45Znever http://www.redacre.com/insights/300614162/biotech-investing-another-potential-red-flag-company2014-07-05T17:05Znever http://www.redacre.com/insights/2014/jul/23/q2-2014-biotech-earnings-preview2014-12-15T23:19Znever http://www.redacre.com/insights/160814164/als-ice-bucket-challenge-accepted2014-10-27T10:13Znever http://www.redacre.com/biotech-earnings-preview-q3-20142015-01-04T22:19Znever http://www.redacre.com/case-studies/bluebird-bio2015-03-22T14:22Znever http://www.redacre.com/insights/2012/nov/06/vivus-pharmaceuticals-q3-results-trigger-selloff-and-read-through-arena2014-05-27T01:46Znever http://www.redacre.com/polls/achn/what-viral-load-reduction-will-ach-3422-deliver2014-12-24T12:55Znever http://www.redacre.com/biotech-minute/biotech-binary-event-watch/december-20142015-02-12T15:12Znever http://www.redacre.com/marketnotes/2015/jan/15/ibb-post-jpm-sell2015-01-16T04:19Znever http://www.redacre.com/terms-of-service2015-01-22T19:24Znever0.4 http://www.redacre.com/insights/2012/nov/08/savient-pharmaceuticals-q3-earnings-release-why-stock-sold2012-11-10T13:27Znever http://www.redacre.com/case-studies/32-precent-gain-15-days2018-07-18T21:23Znever http://www.redacre.com/insights/150515181/video-biotech-binary-event-watch-may-june-20152015-06-20T12:27Znever http://www.redacre.com/education/chocolate-for-weight-loss-con-teaches-valuable-lesson-for-biotech-investors2018-07-18T21:25Znever http://www.redacre.com/insights/2015/aug/14/video-binary-event-watch-august-september-20152015-08-14T22:46Znever http://www.redacre.com/insights/260116189/video-biotech-binary-event-watch-relypsa2016-01-27T02:21Znever http://www.redacre.com/about2013-01-19T20:53Znever http://www.redacre.com/insights/140316191/biotech-shatters-rule-jumps-4002016-03-15T22:24Znever http://www.redacre.com/insights/2016/mar/18/did-synergy-pharmaceuticals-do-bad-deal2016-06-15T07:59Znever http://www.redacre.com/insights/2012/oct/18/seeking-alpha-questcor-bear-raid-analysis2012-11-24T22:10Znever http://www.redacre.com/insights/2012/nov/26/acadia-pharmaceuticals-clinical-trial-data-release-tomorrow-market-sentiment2014-05-27T01:46Znever http://www.redacre.com/insights/2012/nov/29/amarin-delays-saleforce-hiring-outlook-bullish2012-11-30T14:18Znever http://www.redacre.com/insights/2012/dec/10/amarin-will-test-key-support-levels-nce-still-play2014-05-27T01:45Znever http://www.redacre.com/insights/2012/dec/17/synergy-pharmaceuticals-stock-undervalued-ahead-3-major-events2013-01-10T18:00Znever http://www.redacre.com/insights/2012/dec/18/arena-pharmaceuticals-belviq-moves-closer-market-tomorrow2013-02-09T01:16Znever http://www.redacre.com/insights/2012/dec/24/questcor-amarin-alexza-synergy-and-year-end-notes2012-12-25T13:56Znever http://www.redacre.com/insights/2012/oct/12/seeking-alpha-arena-pharmaceuticals-pipeline-advancement-first-several-upcoming2014-05-27T01:47Znever http://www.redacre.com/insights/2012/dec/27/synergy-pharmaceuticals-trial-start-bullish-upcoming-clinical-data-release2013-01-08T20:18Znever http://www.redacre.com/fundperformance/20122014-05-08T18:18Znever0.4 http://www.redacre.com/insights/2013/jan/15/synergy-pharmaceuticals-whats-happened-whats-next-and-explaining-tweet2013-04-09T21:17Znever http://www.redacre.com/insights/2013/jan/18/why-amarin-poped-ahead-orange-book-update2014-05-27T01:42Znever http://www.redacre.com/insights/2013/jan/23/amarin-anchor-patent-allowed-and-us-launch2014-05-27T01:42Znever http://www.redacre.com/insights/2013/jan/29/celsion-simple-model-determine-fair-value2013-01-29T11:42Znever http://www.redacre.com/insights/2013/feb/01/celsion-management-thinks-stock-over-valued2013-02-21T11:10Znever http://www.redacre.com/insights/2013/feb/22/celsion-dilutes-fifty-percent2013-02-23T13:50Znever http://www.redacre.com/insights/2013/mar/01/biotech-binary-event-watch-march-20132014-05-27T01:40Znever http://www.redacre.com/insights/2012/oct/10/seeking-alpha-amarin-nce-decision-delayed-again-what-8-k-really-tells-us2014-05-27T01:48Znever http://www.redacre.com/insights/2013/mar/14/ziopharms-palifosfamide-trial-results-bulls-bears-and-trade2014-05-27T01:40Znever http://www.redacre.com/sectorwatch/healthcare/archive/2018/apr/272018-04-27T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/apr/302018-04-30T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/012018-05-01T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/022018-05-02T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/032018-05-03T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/042018-05-04T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/072018-05-07T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/092018-05-09T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/102018-05-10T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/112018-05-11T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/142018-05-14T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/152018-05-15T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/162018-05-16T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/172018-05-17T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/182018-05-18T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/may/212018-05-21T20:30Znever0.8 http://www.redacre.com/insights/2012/oct/08/seeking-alpha-savient-tang-rally-over-whats-next2014-05-27T01:48Znever http://www.redacre.com/insights/2013/apr/11/biotech-binary-event-watch-april-2013-part-ii-biotechs-super-tuesday2013-05-02T18:33Znever http://www.redacre.com/insights/2013/apr/10/biotech-binary-event-watch-april-2013-part-12013-04-10T11:53Znever http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/042018-09-04T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/052018-09-05T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/062018-09-06T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/072018-09-07T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/102018-09-10T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/112018-09-11T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/122018-09-12T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/132018-09-13T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/142018-09-14T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/172018-09-17T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/182018-09-18T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/192018-09-19T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/202018-09-20T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/212018-09-21T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/242018-09-24T21:27Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/252018-09-25T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/262018-09-26T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/272018-09-27T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/sep/282018-09-28T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/oct/012018-10-01T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/oct/022018-10-02T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/oct/032018-10-03T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/oct/042018-10-04T20:30Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2018/oct/052018-10-05T20:30Znever0.8 http://www.redacre.com/insights/2013/apr/24/pain-free-trade-future-pfizers-remoxy2014-05-27T01:34Znever http://www.redacre.com/insights/2012/oct/05/seeking-alpha-acadia-pharmaceuticals-breaking-out-second-leg2012-11-21T11:40Znever http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/202019-03-20T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/212019-03-21T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/222019-03-22T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/252019-03-25T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/262019-03-26T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/272019-03-27T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/282019-03-28T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/mar/292019-03-29T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/apr/012019-04-01T20:29Znever0.8 http://www.redacre.com/sectorwatch/healthcare/archive/2019/apr/022019-04-02T20:29Znever0.8 http://www.redacre.com/insights/2012/sep/27/seeking-alpha-amarin-good-entry-point-ahead-major-news-next-month2014-05-27T01:49Znever http://www.redacre.com/weeklyreview/2013/jun/30/red-acre-review-week-ending-june-28-20132014-05-09T10:41Znever http://www.redacre.com/weeklyreview/2013/jul/07/week-ending-july-5-20132014-05-28T18:24Znever http://www.redacre.com/insights/2013/aug/06/mannkind-corporations-afrezza-positive-trials-further-capital-raises-ahead2016-01-05T14:17Znever http://www.redacre.com/insights/2013/jul/15/vivus-management-moves-signal-desperation2014-05-27T01:20Znever http://www.redacre.com/weeklyreview/2013/jul/28/week-ending-july-19-20132015-10-25T16:04Znever http://www.redacre.com/insights/2012/sep/11/seeking-alpha-amarin-confirms-nce-delay-what-look-now2012-11-21T11:40Znever http://www.redacre.com/weeklyreview/2013/aug/18/week-ending-august-9-20132014-05-28T18:20Znever http://www.redacre.com/insights/2012/sep/10/getting-ahead-curve-case-study-amarin-corp2014-05-22T14:19Znever http://www.redacre.com/weeklyreview/2013/sep/22/week-ending-september-20-20132014-07-18T15:12Znever